

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

ENZO LIFE SCIENCES, INC.

Plaintiff,

v.

HOLOGIC, INC.

Defendant.

Civil Action No. 1:12-cv-00276-LPS

JURY TRIAL DEMANDED

SECOND AMENDED COMPLAINT

Plaintiff Enzo Life Sciences, Inc. (“Enzo”), for its Second Amended Complaint against Defendant Hologic, Inc. (“Hologic”) hereby alleges as follows:

PARTIES

1. Plaintiff Enzo is a New York corporation with its principal place of business at 10 Executive Boulevard, Farmingdale, NY 11735.
2. Defendant Hologic is a Delaware corporation with its principal place of business at 35 Crosby Drive, Bedford, MA 01730.

NATURE OF THE ACTION

3. This is a civil action for infringement of United States Patent No. 6,992,180 (“the ‘180 Patent”) under the Patent Laws of the United States, 35 U.S.C. § 1 *et seq.*

JURISDICTION AND VENUE

4. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).
5. This Court has personal jurisdiction over Hologic because, among other things, Hologic has committed, aided, abetted, contributed to, and/or participated in the commission of patent infringement in this judicial district and elsewhere that led to foreseeable harm and injury

to Enzo. Moreover, Hologic is a Delaware corporation which, having availed itself of Delaware's corporate laws, is subject to personal jurisdiction in Delaware.

6. This Court also has personal jurisdiction over Hologic because, among other things, Hologic has established minimum contacts within the forum such that the exercise of jurisdiction over Hologic will not offend traditional notions of fair play and substantial justice. Moreover, Hologic has placed products that practice the claimed inventions of the '180 Patent into the stream of commerce with the reasonable expectation and/or knowledge that purchasers and users of such products were located within this District. Hologic has sold, advertised, marketed, and distributed products in this District that practice the claimed inventions of the '180 Patent.

7. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

The Patent-In-Suit

8. United States Patent No. 6,992,180, entitled "Oligo- Or Polynucleotides Comprising Phosphate-Moiety Labeled Nucleotides," was duly and legally issued by the United States Patent and Trademark Office on January 31, 2006. A copy of the '180 Patent is attached hereto as Exhibit A.

9. Enzo is the assignee of the '180 Patent and has the right to sue and recover damages for any current or past infringement of the '180 Patent.

COUNT I

Infringement Of The '180 Patent

10. Paragraphs 1 through 9 are incorporated by reference as if fully stated herein.

11. Hologic, either alone or in conjunction with others, has infringed and continues to infringe, one or more claims of the '180 Patent under 35 U.S.C. § 271, either literally and/or under the doctrine of equivalents, by making, using, offering to sell, selling and/or importing into the United States certain nucleic acid probe products, including without limitation products based upon Invader® technology, for example, and without limitation, Cervista® HPV HR,

Cervista® HPV 16/18, InPlex® CF, and any products as detailed in Enzo's December 5, 2012 Initial Disclosures of Accused Products and Asserted Patents.

12. Hologic has had knowledge of and notice of the '180 Patent and its infringement since at least March 14, 2012, through a letter sent by Enzo to Hologic concerning the '180 Patent and its infringement.

13. Hologic, either alone or in conjunction with others, has induced infringement, and continues to induce infringement, of one or more claims of the '180 Patent under 35 U.S.C. § 271(b). At all relevant times, Hologic actively, knowingly, and intentionally induced others, including without limitation its customers, to use, make, sell, offer for sale, and/or import the Nucleic Acid Probe Products, in a way that Hologic knew or should have known infringes one or more claims of the '180 Patent.

14. Enzo has been and continues to be damaged by Hologic's infringement of the '180 Patent.

15. Hologic's conduct in infringing the '180 Patent renders this case exceptional within the meaning of 35 U.S.C. § 285.

PRAYER FOR RELIEF

WHEREFORE, Enzo respectfully requests that this Court enter judgment against Hologic as follows:

- A. That Hologic has infringed the '180 Patent;
- B. That Enzo be awarded damages adequate to compensate it for Hologic's past infringement and any continuing or future infringement up until the date such judgment is entered, including interest, costs, and disbursements as justified under 35 U.S.C. § 284 and, if necessary to adequately compensate Enzo for Hologic's infringement, an accounting;
- C. That this case be declared an exceptional case within the meaning of 35 U.S.C. § 285;
- D. A preliminary and permanent injunction preventing Hologic, and those in active concert or participation with Hologic, from directly and/or indirectly infringing the '180 Patent;

E. A judgment requiring that, in the event a permanent injunction preventing future acts of infringement is not granted, Enzo be awarded a compulsory ongoing licensing fee; and

F. That Enzo be awarded such other and further relief at law or equity as this Court deems just and proper.

DEMAND FOR JURY TRIAL

Plaintiff Enzo hereby demands a trial by jury on all claims and issues so triable.

Dated: March 7, 2013

Respectfully submitted,

/s/Brian E. Farnan
Brian E. Farnan (Bar No. 4089)
FARNAN LLP
919 North Market Street
12th Floor
Wilmington, DE 19801
(302) 777-0300
(302) 777-0301
bfarnan@farnanlaw.com

Counsel for Plaintiff

Of Counsel:
John M. Desmarais
Michael P. Stadnick
Xiao Li
Joseph C. Akalski
Lauren M. Nowierski
DESMARAIS LLP
230 Park Avenue
New York, NY 10169
(212) 351-3400 (Tel)
(212) 351-3401 (Fax)
jdesmarais@desmaraisllp.com
mstadnick@desmaraisllp.com
xli@desmaraisllp.com
jakalski@desmaraisllp.com
lnowierski@desmaraisllp.com